37 results about "Acyl-CoA carboxylase" patented technology

The present invention provides compounds useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, and methods of using the same.

The present invention provides methods for increasing oil content in Jatropha Curcas L. plants. The invention further provides the cDNA and protein sequences of Jatropha acetyl CoA carboxylase (ACCase) and methods for cloning and expressing the Jatropha ACCase gene to produce transgenic plants with increased oil content.

The invention provides a compound of Formula (I)

or a pharmaceutically acceptable salt of the compound, wherein R¹, R², R³ and R⁴ are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

The invention provides compounds of Formula (1) or a pharmaceutically acceptable salt of said compound, wherein R¹, R², and R³ are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of acetyl-CoA carboxylase enzyme(s) in an animal.

Pyrrolidine derivatives which are inhibitors of acetyl-CoA carboxylase(s) and their use in the treatment of obesity and type-2 diabetes. An exemplary compound is 2-(4-(1-[5-Chloro-6-(2-hydroxy-2-methyl-propoxy)-pyrimidin-4-yl]-(R)-pyrrolidin-3-yloxy)-phenyl)-N-cyclopropyl-propionamide.

The invention relates to a herbicide composition and an application method thereof. The composition comprises an active component A and an active component B, wherein the component A is selected froma compound represented by a following general formula, and the component B is one selected from acetyl-CoA carboxylase (ACC) inhibitor type herbicides. The herbicide composition disclosed by the invention is particularly suitable for preventing and removing weeds with tolerance or resistance to organophosphorus herbicides, especially glyphosate.

The invention discloses a method for improving the fermentation level of salinomycin by increasing supply of precursors. The method comprises the following steps: doubling acetyl coA carboxylase genes from streptomyces coelicolor, methyl malonyl coA mutase genes from streptomyces albus DSMZ41398 and crotonoyl coA reductase genes from the streptomyces albus DSMZ41398 on the chromosomes of the streptomyces albus DSMZ41398 through an integrating vector pSET152 respectively to increase supply of three precursors required for synthesizing salinomycin so as to increase the salinomycin yield. According to the method, the final fermentation yield of engineering strain salinomycin is increased by 260% and the shake flask level of a lab reaches 2 g/L.

The present invention relates to methods of treating and/or preventing acne in patients comprising the step of administering to patients in need of such treatment a therapeutically effective amount of an ACC inhibitor or a pharmaceutically acceptable salt thereof.

Methods and means are provided to increase the oil content of plants, particularly oleaginous plants by preventing feedback inhibition by 18:1-Coenzyme A or 18:1-Acyl Carrier Protein of the acetyl CoA-carboxylase enzyme in cells of these plants in various manners.

The invention belongs to the field of medical chemistry and relates to a compound used as an ACC (Acetyl CoA Carboxylase) inhibitor and application thereof. Specifically, the invention provides a compound shown as a formula I or isomers, pharmaceutically acceptable salts, solvates, crystals or prodrugs thereof, a preparation method of the compounds, a pharmaceutical composition containing the compounds and application of the compounds or the pharmaceutical composition to treatment and/or prevention ACC expression related diseases, such as fibrotic diseases, metabolic diseases, cancers or tissue proliferation diseases. The compound provided by the invention has very good inhibition activity on ACC and is very hopefully prepared into a treatment medicine for the fibrotic diseases, the metabolic diseases, the cancers or the tissue proliferation diseases. The formula I is shown in the description.

A system for carbon fixation is provided. The system comprises enzymes which catalyze reactions of a carbon fixation pathway, wherein at least one of the reactions of the carbon fixation pathway is a carboxylation reaction, wherein products of the reactions of the carbon fixation pathway comprise oxaloacetate and malonyl-CoA, wherein an enzyme which performs the carboxylation reaction is selected from the group consisting of phophoenolpyruvate (PEP) carboxlase, pyruvate carboxylase and acetyl-CoA carboxylase and wherein an export product of the carbon fixation pathway is glyoxylate. Additional carbon fixation pathways are also provided and methods of generating same.

The invention provides recombinant bacteria for synthesizing succinic acid from a fixed amount of carbon dioxide, as well as a construction method and application of the recombinant bacteria, and belongs to the field of gene engineering and fermentation engineering. A recombinant bacteria host is escherichia coli, which can express a gene accADBC of acetyl-CoA carboxylase, a gene mcr of malonyl CoA reductase, a gene pcs of propionyl CoA synthase, a gene pcc of propionyl CoA carboxylase, a gene mcE of methylmalonyl-CoA isomerase, a gene mcM of methylmalonyl-CoA mutase and a gene sucCD of succinyl-coenzyme A synthase. According to the construction method, recombinant carriers pACYCDuet-accADBC-pcs and pETDuet-mcr-pcc-sucCD-mcEM are transformed into a host cell. The recombinant bacteria constructed through the construction method can adopt glucose serving as a unique carbon source to synthesize the succinic acid, and fermentation is performed for 48 hours, thus obtaining the succinic acid with the concentration of 6.06 g/L.

This invention relates to methods of using inhibitors of the enzyme acetyl-CoA carboxylase (ACC) for the treatment, prevention, inhibition or alleviation of diseases associated with neuronal hypometabolism and/or loss of cognitive function caused by reduced neuronal metabolism such as, for example, Age Associated Memory Impairment (AAMI), Mild Cognitive Impairment (MCI), Alzheimer's disease, Parkinson's disease, Friedreich's Ataxia (FRDA), GLUT1-deficient Epilepsy, Leprechaunism and Rabson-Mendenhall Syndrome, Coronary Arterial Bypass Graft (CABG) dementia, anesthesia induced memory loss, Huntington's disease and many others.

The present invention relates to a method for the crystallization of protein using nanoparticles as nucleation agents. Precisely, the inventors performed the crystallization of such proteins as Bacillus subtilis YesR, chicken egg white lysozyme, bovine serum albumin, Alicyclobacillus acidocaldarius acetyl-CoA carboxylase, and Listeria monocytogenes hypothetical protein which have his-tag at amino terminal by using gold nanoparticles in diverse sizes and shapes in the presence of Ni²⁺ ions. As a result, it was confirmed that the chance of successful crystallization was higher with the gold nanoparticles than without the gold nanoparticles and the various crystallization conditions were successfully screened. Therefore, the method for inducing nucleation of the invention can be advantageously used for the disclosure of protein structure by increasing the chance of successful crystallization of protein.